Michael Hofman
@DrMHofman
Working together to improve patient outcomes with personalised medicine & precision oncology: theranostics. PET/CT, prostate cancer ☢️ Prof 🇦🇺
Augerlicious: Terbium-161 Double Punch to Cancer Cells Live & free webinar, register: link.prostic.org/webinar Sep 18 or 17 (check your time-zone) Is Terbium-161 superior to Lutetium-177? You'll hear about the latest clinical trials, experience and translational research from…
Thanks @_ShankarSiva @declangmurphy @DrMHofman @DrBenTran @RenuEapen #LewisAu for your welcome & hospitality @PeterMacCC @Melbourne — @andyzwang & I enjoyed tumor board & exchanging GU onc insights!
"Many lives are lost not because they don't have access to newest technology or drugs, but because they didn't receive proven treatments in time" @oncology_bg wonderful to meet you @ANZUPtrials #anzup25 #CommonSenseOncology
Thank you @ANZUPtrials @Prof_IanD @doccharris @DrL_Krieger for the invitation to share my thoughts with the ANZUP audience and for such a warm hospitality. Had a fabulous time, met new colleagues, built foundations for new collaborations, and hopefully for better outcomes for our…
Wonderful collaborative efforts w landscape of @ANZUPtrials for the spectrum of #prostatecancer! #LisaHorvath @AzadOncology @DrMHofman @ChrisSweens1 @Prof_IanD
🚨 First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study 📖 Read now: thelancet.com/journals/lanon… @SNM_MI #ProstateCancer
Thanks for advertising @APCCC_Lugano and do not forget that registration is now open for 2026 on apccc.org for everyone interested. And we will for the first time also accept abstracts! Stay tuned for other news!
🌏 APCCC is everywhere and now it’s in Seoul! Global minds unite for prostate cancer care. Genitourinary Masterclass! @APCCC_Lugano #ProstateCancer #Oncology #GlobalOncology @OncoAlert @Silke_Gillessen @AOmlin
Congrats to Jennifer Doubell OAM – who was last night named a Distinguished Fellow of Peter Mac, our highest honour, for her extraordinary impact on cancer research and care. Read more: petermac.org/about-us/news-…
Snippets from new GU Cast, beachside chat with @DrMHofman on #ASCO25 theranostics highlights @RenuEapen @declangmurphy
Beachside GU Cast with @DrMHofman @RenuEapen @declangmurphy to hear Michael’s #ASCO25 PSMA theranostic highlights. Plus some CAIX renal excitement youtu.be/xNpEC3bF_sw?si…
Two comprehensive reviews on new bispecific antibodies in #lymphoma made pretty and online @Haematologica #lymsm @AdrianMinson @nancybartlettMD
#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in @TheLancetOncol : thelancet.com/journals/lanon… 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣Very few…
620 of 660 patients randomised in #PRIMARY2 🎯Bringing PSMA PET from staging to DIAGNOSIS 🏁The finishing line approaches Thank-you⭐investigators @ButeauJames @drlouiseemmett @DrDanielMoon @declangmurphy + many more Supported by @PeterMacCC @SVHSydney @PCF_Science @pros_tic…
Can we kill the bone scan? @DrSpratticus @caseccc presents on bone scan obsolescence in #ProstateCancer imaging. Dr. Spratt demonstrates that they fail to detect cancer with sufficient sensitivity compared to PSMA PET, having no role in diagnosis or staging across disease states.…
🥳 Today, we randomised the final patient on @TROGfightcancer 19.06 DECREASE trial! This trial randomised patients with prostate cancer who were becoming resistant to hormone therapy, without evidence of metastases on bone or CT scan, to Darolutamide +/- Stereotactic…
Congratulations to @EdmondMKwan who was a finalist in the 2024/25 Victorian Premier’s Awards for Health & Medical Research - Clinical Researcher Award category for his ctDNA research work into the @ANZUPtrials #TheraP trial anzup.org.au/news/anzups-th…
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant #ProstateCancer #VIOLET: A single-centre, single-arm, phase I/II study. Presentation by @ButeauJames @PeterMacCC #SNMMI25 written coverage by @RKSayyid…
The first patient has been imaged in a study evaluating the efficacy of the diagnostic agent [68Ga]Ga-DPI-4452 in detecting ccRCC in patients with an indeterminate renal mass. #kcsm @DrMHofman urologytimes.com/view/trial-lau…
🚨 #SNMMI25 How about Terbium-161? @ButeauJames @PeterMacCC presents first-in-human data on [¹⁶¹Tb]Tb-PSMA-I&T for #mCRPC: dual-action β + Auger emitter hits both bulky tumors and micrometastases. #VIOLET trial shows 70% PSA50, 40% PSA90, low toxicity, and 11 mo rPFS. 💥 A new…